Table 5 Adjusted absolute efficacy for biologic DMARDS + MTX at 24/26 and 48/54 weeks
Treatments relative to effect | Absolute HAQ CFB at 24/26 weeks (95% CrL)* | Absolute HAQ CFB at 48/54 weeks (95% CrL)** | Proportion (%) of patients with ACR-50 at 24/26 weeks (95% CrL) * | Proportion (%) of patients with ACR-50 at 48/54 weeks (95% CrL)** | Proportion (%) of patients with DAS28 < 2.6 at 24/26 weeks (95% CrL)* | Proportion (%) of patients with DAS28 < 2.6 at 48/54 weeks (95% CrL)* |
|---|---|---|---|---|---|---|
Placebo + MTX | -0.29 (-0.31; -0.26) | -0.29 (-0.34; -0.24) | 11.9% (9.7%; 14.0%) | 12.5% (9.4%; 15.5%) | 2.6% (1.4%; 4.1%) | 7.0% (4.7%; 9.8%) |
Adalimumab + MTX | -0.61 (-0.77; -0.46) | -0.63 (-0.74; -0.51) | 53.5% (28.0%; 77.9%) | 49.5% (35.9%; 63.5%) | Â | Â |
Certolizumab Pegol + MTX | -0.67 (-0.82; -0.53) | -0.71 (-0.81; -0.61) | 57.3% (31.2%; 79.9%) | 51.7% (38.1%; 66.1%) | 33.4% (4.4%; 90.0%) | Â |
Etanercept + MTX | -0.56 (-0.75; -0.38) | -0.63 (-0.87; -0.39) | 30.7% (15.6%; 65.2%) | 43.2% (31.8%; 54.9%) | 6.9% (1.0; 31.5%) | 18.7% (1.8%; 73.3%) |
Golimumab + MTX | -0.63 (-0.86; -0.39) | Â | 34.6% (9.7%; 69.2%) | Â | 9.6% (1.4%; 42.4%) | Â |
Infliximab + MTX | -0.48 (-0.62; -0.33) | -0.48 (-0.59; -0.36) | 26.0% (6.6%; 57.4%) | 28.1% (19.4%; 38.3%) | 12.6% (1.9%; 53.3%) | 28.8% (1.9%; 89.5%) |
Rituximab + MTX | -0.49 (-0.68; -0.31) | -0.59 (-0.91; -0.27) | 35.3% (14.8%; 61.9%) | 64.1% (32.4%; 91.3%) | Â | Â |
Tocilizumab + MTX | -0.49 (-0.73; -0.26) | Â | 47.5% (16.1%; 78.6%) | Â | 71.0% (19.0%; 98.9%) | Â |
Abatacept + MTX | -0.58 (-0.70; -0.46) | -0.58 (-0.66; -0.50) | 31.7% (15.9%; 50.6%) | 35.4% (27.3%; 43.3%) | 11.3% (3.7%; 28.8%) | 40.2% (10.4%; 80.3%) |